Valuation : AbbVie Inc.

Market Cap 454B 391B 371B 336B 630B 43,408B 634B 4,402B 1,693B 22,084B 1,706B 1,669B 69,783B P/E 2026 *
32.9x
P/E 2027 * 24.5x
Enterprise Value 516B 445B 421B 382B 716B 49,292B 719B 4,999B 1,922B 25,078B 1,938B 1,895B 79,242B EV / Sales 2026 *
7.63x
EV / Sales 2027 * 6.9x
Free-Float
95.71%
Yield 2026 *
2.67%
Yield 2027 * 2.8%
09-10 Abbvie Declares Quarterly Dividend, Payable on November 16, 2026 CI
09-10 AbbVie Keeps Quarterly Dividend at $1.73 a Share, Payable Nov. 16 to Holders of Record Oct. 15 MT
09-10 AbbVie Announces Positive Phase 3 Atogepant Results in Menstrual Migraine CI
09-10 AbbVie's Menstrual Migraine Treatment Meets Primary, Secondary Endpoints in Phase 3 Trial DJ
09-10 AbbVie's menstrual migraine treatment meets late-stage study goal RE
09-10 AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study MT
09-10 AbbVie's migraine treatment meets late-stage study goal RE
09-10 HSBC Adjusts Price Target on AbbVie to $315 From $300, Keeps Buy Rating MT
09-09 AbbVie Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 10:15 AM
09-08 BofA Securities Adjusts Price Target on AbbVie to $282 From $276 MT
09-03 AbbVie Announces Positive Topline Results From The Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate And Progression-Free Survival In Patients With Relapsed/Refractory Multiple Myeloma CI
09-03 AbbVie Inc. completed the acquisition of Apogee Therapeutics, Inc. from Fairmount Healthcare Fund II L.P managed by Fairmount Funds Management LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P managed by Venrock Management, LLC and other shareholders. CI
09-03 AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints MT
1 day+0.83%
1 week+0.26%
Current month+0.27%
1 month+2.81%
3 months+14.39%
6 months+12.93%
Current year+12.53%
1 week 246.77
Extreme 246.7701
259.61
1 month 246.77
Extreme 246.7701
266.96
Current year 190.75
Extreme 190.75
267.47
1 year 190.75
Extreme 190.75
267.47
3 years 135.85
Extreme 135.85
267.47
5 years 105.56
Extreme 105.56
267.47
10 years 55.06
Extreme 55.0623
267.47
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Date Insider Type Main position Quantity % Market Cap. Importance
14/08/26 Exercice

Executive/Senior Manager

98,130 0.0056%
30/06/26 Free

Director

62 0.0000%
30/06/26 Free

Director

134 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+0.83%+0.26%+16.76%+72.52% 454B
-0.65%-2.93%+47.52%+87.34% 994B
-0.29%-3.51%+48.78%+63.27% 640B
-0.38%-3.59%+28.24%+35.57% 337B
-0.09%-13.54%+10.08%+26.87% 261B
-0.43%-2.48%-2.07%+11.48% 246B
-1.34%-13.70%+33.47%+44.18% 204B
-3.44%-7.51%-20.08%-59.58% 190B
-0.75%-4.82%+21.94%+86.55% 178B
+0.25%-2.57%+11.50%-18.33% 158B
Average -0.57%-5.44%+19.61%+34.99% 366.28B
Weighted average by Cap. -0.45%-4.34%+29.07%+52.52%

Financials

2026 *2027 *
Net sales 67.59B 58.23B 55.14B 49.98B 93.76B 6,457B 94.24B 655B 252B 3,285B 254B 248B 10,380B 73.49B 63.32B 59.96B 54.34B 102B 7,021B 102B 712B 274B 3,572B 276B 270B 11,287B
Net income 14.08B 12.13B 11.49B 10.41B 19.53B 1,345B 19.63B 136B 52.46B 684B 52.88B 51.72B 2,162B 19.09B 16.45B 15.57B 14.11B 26.48B 1,824B 26.61B 185B 71.12B 928B 71.68B 70.11B 2,932B
Net Debt 61.59B 53.07B 50.25B 45.55B 85.45B 5,884B 85.88B 597B 229B 2,994B 231B 226B 9,460B 53.09B 45.74B 43.31B 39.26B 73.65B 5,072B 74.03B 514B 198B 2,580B 199B 195B 8,154B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
11/09/26 $257.12 +0.83% 4,308,856
10/09/26 $255.00 +1.63% 4,397,653
09/09/26 $250.91 +0.86% 3,866,951
08/09/26 $248.78 -2.99% 5,572,102
04/09/26 $256.46 -1.44% 4,729,800
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
257.12USD
Average target price
277.31USD
Spread / Average Target
+7.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!